ARMYDA: Atorvastatin for Reduction of Myocardial Damage During Angioplasty

      -Pretreatment with Atorvastatin Compared with Placebo in Patients Scheduled for Elective PCI on the Risk of Procedural Myocardial Injury by Dr. V. Pasceri, et al. (2004)

ARMYDA-2: Atorvastatin for Reduction of Myocardial Damage During Angioplasty-2

      -300 mg vs. 600 mg of Plavix During PCI by Dr. Germano Di Sciascio (ACC 2005)

ARMYDA-4: Atorvastatin for Reduction of Myocardial Damage During Angioplasty-4

      -Prospective, Multicenter, Randomized Double-blind Trial Investigating Influence on PCI Outcome of Additional 600 mg Clopidogrel Load in Patients on Chronic Therapy - "ARMYDA-Reload" by Dr. Germano Di Sciascio (TCT 2007)

ARMYDA-5: Atorvastatin for Reduction of Myocardial Damage During Angioplasty-5

      -Prospective, Multicenter, Randomized Trial Investigating Influence on Outcome of in-lab 600 mg Clopidogrel Loading vs. 6-hour Pre-PCI Treatment - "ARMYDA-Preload" by Dr. Germano Di Sciascio (TCT 2007)

CHARISMA: Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management and Avoidance

      -Data Interpretation

      -CHARISMA: The "CAPRIE-like" Cohort by Dr. Deepak L. Bhatt

CHARISMA Genomics Substudy: Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management and Avoidance

      -Trial Overview by Dr. Deepak L. Bhatt, et al.

COGENT: A Prospective, Randomized, Placebo-Controlled Trial of Omeprazole in Patients Receiving Aspirin and Clopidogrel

      -Results by Dr. Deepak L. Bhatt (TCT 2009)

CREDO: Clopidogrel for the Reduction of Events During Observation

      -Pretreatment Compared with No Pretreatment with Clopidogrel Prior to Elective PCI

CURE & PCI-CURE: Clopidogrel in Unstable Angina to Prevent Recurrent Events & Clopidogrel in Unstable Angina to Prevent Recurrent Ischemic Events in Patients Undergoing Percutaneous Coronary Intervention

      -Results

CURRENT OASIS-7: Clopidogrel Optimal Loading Dose Usage to Reduce Recurrent Events/Optimal Antiplatelet Strategy for Interventions

      -A 2x2 Factorial Randomized Trial of Optimal Clopidogrel and Aspirin Dosing in Patients with ACS Undergoing an Early Invasive Strategy with Intent for PCI by Dr. Shamir R. Mehta

ISAR-DESIRE: Intracoronary Stenting and Antithrombotic Regimen - Drug-Eluting Stents for In-Stent Restenosis

      -Clopidogrel vs. Placebo Among Patients with ST Elevation Myocardial Infarction (MI) Also Treated with Aspirin by Dr. A. Kastrati (European Society of Cardiology Congress 2004)

ISAR-REACT: Intracoronary Stenting and Antithrombotic Regimen - Rapid Early Action For Coronary Treatment

      -Evaluates Role of Abciximab in Reducing Postprocedure Ischemic Complications in Low-Risk Patients Pretreated with Clopidogrel who Undergo Coronary Stenting (ACC 2003)

ISAR-SWEET: Intracoronary Stenting and Antithrombotic Regimen - Is Abciximab a Superior Way to Eliminate Elevated Thrombotic Risk in Diabetics?

      -Trial Overview by Dr. Julinda Mehilli (AHA 2004)

PREMIER Registry: Prospective Registry Evaluating Outcomes After Myocardial Infarction: Events and Recovery Quality Improvement Registry

      -Discontinuation of clopidogrel associated with higher mortality following drug eluting stent implantation in STEMI, adds to concerns of BASKET Late

PRINCIPLE-TIMI 44: Prasugrel in Comparison to Clopidogrel for Inhibition of Platelet Activation and Aggregation - Thrombolysis In Myocardial Infarction (TIMI) 44

      -Trial Overview by Dr. Stephen D. Wiviott (2007)

TRITON-TIMI 38: Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition with Prasugrel - Thrombolysis In Myocardial Infarction (TIMI) 38

      -The Risk of CV Events for Patients Treated with Clopidogrel or Prasugrel in Combination with a Proton Pump Inhibitor: Results from the TRITON-TIMI 38 Trial by Dr. Michelle O'Donoghue, et al. (ESC 2009)

      -Trial Overview (AHA 2007)

(Return to Contents)

Clopidogrel Pre-Treatment Studies

Pretreatment with Thienopyridines

      -Emerging Data Regarding the Potential Benefits of Early Initiation of Clopidogrel Among ACS Patients by Dr. C. Michael Gibson

(Return to Contents)

Clopidogrel Loading Dose Studies

Early Stent Thrombosis

      -Tailored Clopidogrel Loading Dose According to Platelet Reactivity Monitoring Decrease Early Stent Thrombosis by Dr. Laurent Bonello, et al.

Superiority of 600 mg of Clopidogrel as a Loading Dose

      -A MetaAnalysis by Dr. G. Biondi-Zoccai, et al. (SCAI 2007)

(Return to Contents)

Platelet Physiology

Antiplatelet Resistance

      -What Does It Mean and What Should/Can We Do About It? by Dr. Dominick Angiolillo (CRT 2008)

Antiplatelet Therapy

      -Antiplatelet Therapy Use After Discharge Among Acute Myocardial Infarction Patients with In-hospital Bleeding by Dr. Tracy Y. Wang (2008)

Clopidogrel Non-Responsiveness

      -Clinical Implications of Clopidogrel Non-Responsiveness by Dr. Dominick Angiolillo

Clopidogrel Response

      -Clopidogrel Response Variability and Resistance by Dr. Paul A. Gurbel

Drug-Eluting Stent

      -Impact of Platelet Reactivity Following Clopidogrel Administration on Drug-Eluting Stent Thrombosis by Dr. David Antoniucci

      -Clopidogrel Use and Long-term Clinical Outcomes After Drug-Eluting Stent Implantation by Dr. Eric Eisenstein, et al.

Dual Antiplatelet Treatment

      -Long-Term Outcomes in Patients Undergoing Coronary Stenting on Dual Oral Antiplatelet Treatment Requiring Oral Anticoagulant Therapy by Dr. R. Rossini, et al. (2008)

      -Prevention of Premature Discontinuation of Dual Antiplatelet Therapy in Patients with Coronary Artery Stents by Dr. Cindy L. Grines, et al. (2007)

SUNSET Registry

      -Clopidogrel Use and Death/MI After Stent Implantation in a Diabetic Population: Results from the SUNSET Registry by Dr. Somjot S. Brar, et al. (SCAI 2007)

(Return to Contents)

Genomics

Cytochrome P450 2C19 Polymorphism

      -Cytochrome P450 2C19 Polymorphism in Young Patients Treated with Clopidogrel After Myocardial Infarction: A Cohort Study by Dr. Jean-Philippe Collet, et al. (2008)

(Return to Contents)

Who Are We?    Slide Downloading Policy   Financial Disclosure    We Do Not Promote Off Label Product Use    Copyright    Source of Slides    Editorial Policy    Links Policy    Privacy Policy   Access    CME Programs